Clinical trial · Observational
Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia
CREEK is a Multicenter Retrospective Study to Understand the Clinical Characteristics, Treatment Pathway and Resource Utilization for Patients With Chronic Lymphocytic Leukemia in International Region.
NCT04964908CI-TRIAL-00074135CREEKcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A Multicenter Retrospective Study to understand the clinical characteristics, treatment pathway and resource utilization for patients with chronic lymphocytic leukemia A retrospective, multi-centre, observational study to describe disease characteristics, treatment patterns, treatment-related outcomes, and resource utilization for Chronic Lymphocytic Leukemia (CLL) patients in multiple international regions
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (6)
- measure
- To describe the clinical characteristics for with chronic lymphocytic leukemia (CLL) patients
- timeFrame
- 5 year
- description
- To describe the clinical characteristics for with chronic lymphocytic leukemia (CLL) patients, recording the patient characteristic: \- Demographics: (Age, gender, race, nationality, Performance status, Tobacco use, Family history of malignancies)
- measure
- Calculation of Epidemiological Measure(s) of Interest
- timeFrame
- 5 years
- description
- Calculation of Epidemiological Measure(s) of Interest e.g., descriptive statistics, hazard ratios, incidence rates, test/retest reliability)
- measure
- To describe the clinical characteristics for with chronic lymphocytic leukemia (CLL) patients
- timeFrame
- 5 Years
- description
- To describe the clinical characteristics for with chronic lymphocytic leukemia (CLL) patients, recording the patient characteristic: * Laboratory Status: * CBC: Hemoglobin, Total leucocytic count, neutrophils, lymphocytes, and platelets * Renal functions: serum creatinine, Urea, eGFR * Hepatic function: ALT and AST * Concomitant medications: * Antagonists of vitamin K * Oral Anticoagulants: rivaroxaban, apixaban, dabigatran * Proton pump inhibitors (PPIs) * H2 Antagonists * Antacids * Others
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Primary diagnosis of Chronic Lymphocytic Leukemia (CLL) * Initiated CLL treatment (including 1st line, 2nd line, or Subsequent lines of treatment) within the period between 01 June 2016, and 12 months before data collection \- For GCC pilot cohort patients: treatment-naive CLL patients diagnosed between 01 June 2016, and 12 months before data collection. * Available medical records at the participating site reflecting at least 12 months of follow-up after starting on treatment (except in the case of the participant death within one year following treatment initiation). * Provision of informed consent by the patient or next of kin/legal representative (for deceased patients at study entry, unless a waiver was granted), according to local regulations. * Adult male or female ≥18 years old at the time of diagnosis or according to the age of majority as defined by local regulations). Exclusion Criteria: * Failure to meet one or more of the inclusion criteria. * Any diagnosis of B-cell malignancies other than CLL. * Current or prior use of "acalabrutinib" treatment. * Currently/previously receiving treatment in an interventional clinical trial at the time of entry into this study for indications CLL.
References
Publications (1)
- DERIVEDAbdelmoaty M, Alshehri H, Alamoudi S, Buyukasik Y, Abdelfattah R, Alorabi M, Kamal A, Aboutaleb A, Alhejazi A. Chronic lymphocytic leukaemia in the Middle East: a subgroup analysis from the CREEK study on treatment patterns and outcomes. Expert Rev Anticancer Ther. 2026 Feb;26(2):283-294. doi: 10.1080/14737140.2025.2582649. Epub 2025 Nov 11. PMID 41175395